Home / Market News / $CRL
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Financial Institutions Adjust Price Targets for Charles River Laboratories Following Q3 Earnings

Nov 5, 2026, 7:09 PM UTC · Primary ticker $CRL

Following Charles River Laboratories' Q3 2026 earnings, several financial institutions, including UBS, Jefferies, and Deutsche Bank, increased their price targets for the company. These adjustments reflect analyst reactions to the company's recent financial performance and updated guidance, suggesting a positive outlook from the analyst community.

This filing indicates that multiple financial institutions have raised their price targets for Charles River Laboratories (CRL) after the company's Q3 2026 earnings report. This matters because analyst price target revisions often signal a change in market sentiment and can influence investor perception and stock performance. The short-term implication is a potential positive bump for CRL's stock as these upgrades become public, while the long-term implication suggests continued confidence in the company's fundamentals. For traders, this presents an opportunity to consider long positions in CRL, as the consensus among analysts appears to be strengthening, potentially leading to upward momentum.

$CRL positive Analyst price target increases
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.